Hepatitis B Reactivation in a US Cohort of People With Human Immunodeficiency Virus and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity

Key Points

• To evaluate the risk of hepatitis B virus reactivation in individuals with HIV and anti-HBV core antibody after changing antiretroviral therapy.
• Analyzed a US cohort of individuals with HIV and anti-HBc antibody
• Monitored HBV status after switching from HBV-active to non-HBV-active therapy
• Assessed prior HBsAg status
• Overall HBV reactivation risk was found to be low
• No participants had prior HBsAg positivity
• Findings aid in discussions between providers and patients about treatment options